文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急性肾损伤的通用预测与机制性尿液肽段特征

A universal predictive and mechanistic urinary peptide signature in acute kidney injury.
PubMed 文献 · Crit Care · 2022-11-07
一句话结论在心脏搭桥与ICU患者中,一种204条尿液肽段特征可在4小时内预测AKI(OR 6.13与5.92),优于现有生物标志物,并关联院内死亡(OR 2.62)。

该研究在总计1170例心脏搭桥手术患者(推导与验证队列)及1569例ICU患者(外部队列)中,开发并验证了一种基于尿液肽段的评分,用于预测7天KDIGO定义的AKI。204条源自48种蛋白的肽段可在4小时内区分AKI风险(OR 6.13 [3.96-9.59],p<0.001),性能优于尿NGAL、[IGFBP7].[TIMP2]乘积及临床评分。外部ICU队列中性能相似(OR 5.92 [4.73-7.45],p<0.001),且与院内死亡相关(OR 2.62 [2.05-3.38],p<0.001)。该特征可能有助于早期识别进展为AKI的患者并区分亚表型。

要点

  • 在1170例心脏搭桥患者中,204条尿液肽段特征可在4小时内预测7天KDIGO AKI,OR 6.13 [3.96-9.59],p<0.001,优于尿NGAL、[IGFBP7].[TIMP2]及临床评分。
  • 在1569例ICU患者外部验证中,该特征预测AKI性能相似,OR 5.92 [4.73-7.45],p<0.001。
  • 同一ICU队列中,该肽段特征与院内死亡相关,OR 2.62 [2.05-3.38],p<0.001。
  • 该特征源自48种与溶血、炎症、免疫细胞迁移、先天免疫及细胞生长存活相关的蛋白,可提供机制信息以区分AKI亚表型。

适用人群与场景

  • 推导与验证队列:总计1170例接受重大心脏搭桥手术的患者。
  • 外部验证队列:1569例ICU患者。

诊断标准与关键阈值

  • AKI预测结局采用7天KDIGO分类。

研究设计与关键结果

  • 研究类型:推导与验证队列研究,外加外部ICU队列验证。
  • 推导与验证队列共1170例重大心脏搭桥手术患者,外部队列1569例ICU患者。
  • 识别并验证了204条源自48种蛋白的尿液肽段,用于早期(<4小时)区分患者发生AKI的风险,OR 6.13 [3.96-9.59],p<0.001。
  • 该肽段特征性能优于参考生物标志物尿NGAL和[IGFBP7].[TIMP2]乘积以及临床评分。
  • 在1569例ICU患者外部队列中,特征性能相似,OR 5.92 [4.73-7.45],p<0.001。
  • 在ICU队列中,该特征与院内死亡相关,OR 2.62 [2.05-3.38],p<0.001。

证据类型、等级与局限

  • 证据类型:推导与验证队列研究及外部ICU队列验证。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该尿液肽段特征可在早期(<4小时)识别可能进展为AKI的心脏搭桥手术患者和ICU患者,性能与单一生物标志物相当或更高,并增加机制信息以区分AKI亚表型,作者认为可能为开发针对性治疗提供新途径。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The delayed diagnosis of acute kidney injury (AKI) episodes and the lack of specificity of current single AKI biomarkers hamper its management. Urinary peptidome analysis may help to identify early molecular changes in AKI and grasp its complexity to identify potential targetable molecular pathways.

METHODS: In derivation and validation cohorts totalizing 1170 major cardiac bypass surgery patients and in an external cohort of 1569 intensive care unit (ICU) patients, a peptide-based score predictive of AKI (7-day KDIGO classification) was developed, validated, and compared to the reference biomarker urinary NGAL and NephroCheck and clinical scores.

RESULTS: A set of 204 urinary peptides derived from 48 proteins related to hemolysis, inflammation, immune cells trafficking, innate immunity, and cell growth and survival was identified and validated for the early discrimination (&lt; 4 h) of patients according to their risk to develop AKI (OR 6.13 [3.96-9.59], p &lt; 0.001) outperforming reference biomarkers (urinary NGAL and [IGFBP7].[TIMP2] product) and clinical scores. In an external cohort of 1569 ICU patients, performances of the signature were similar (OR 5.92 [4.73-7.45], p &lt; 0.001), and it was also associated with the in-hospital mortality (OR 2.62 [2.05-3.38], p &lt; 0.001).

CONCLUSIONS: An overarching AKI physiopathology-driven urinary peptide signature shows significant promise for identifying, at an early stage, patients who will progress to AKI and thus to develop tailored treatments for this frequent and life-threatening condition. Performance of the urine peptide signature is as high as or higher than that of single biomarkers but adds mechanistic information that may help to discriminate sub-phenotypes of AKI offering new therapeutic avenues.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Piedrafita A, Siwy J, Klein J, et al. A universal predictive and mechanistic urinary peptide signature in acute kidney injury. Crit Care. 2022. PMID: 36345008. doi:10.1186/s13054-022-04193-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。